Heterocyclic compound

Abstract

A novel heterocyclic compound represented by the following formula (I): ##STR1## wherein X represents an oxygen atom or sulfur atom; R.sup.1 represents a hydrogen atom or halogen atom; R.sup.2 represents a C.sub.4 -C.sub.6 alkyl group, C.sub.2 -C.sub.10 alkoxyalkyl group, C.sub.3 -C.sub.15 alkenyl group, C.sub.7 -C.sub.12 aralkyl group, C.sub.8 -C.sub.18 aralkyloxyalkyl group, C.sub.7 -C.sub.12 aryloxyalkyl group, C.sub.3 -C.sub.10 alkynyl group, C.sub.4 -C.sub.12 alkadienyl group, C.sub.6 -C.sub.18 alkatrienyl group, C.sub.6 -C.sub.12 alkadiynyl group, or C.sub.6 -C.sub.12 alkatriynyl group, said aryloxyalkyl group, alkynyl group, alkadienyl group, alkatrienyl group, alkadiynyl group and alkatriynyl group being capable of having at least one substituent selected from the group consisting of halogen atoms, C.sub.1 -C.sub.4 alkyl group, C.sub.1 -C.sub.4 halogenated alkyl group, phenyl group, hydroxyl group and C.sub.1 -C.sub.4 alkoxy group; and each of R.sup.3 and R.sup.4 independently represents a hydrogen atom, C.sub.1 -C.sub.6 alkyl group, phenyl group or tolyl group, or R.sup.3 and R.sup.4 may be combined together to from a benzene ring which may have at least one halogen atom; or a pharmaceutically acceptable salt thereof. The compound according to the present invention has an effect of inhibiting lipoxygenase and suppresses the formation of leukotrienes and, accordingly, useful for the prevention and treatment of inflammation, rheumatism and various allergic diseases.